Metsera Inc(MTSR) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025 MET-097o, an oral formulation of MET-097i, has been accelerated and ...